stockrow
Saturday 7 November 2026
Export PTHS’s income statement to Excel — free account
Pelthos Therapeutics Inc.
PTHS Healthcare Biotechnology
Pelthos Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.8 million.
- EPS
- −23.1%
- Free cash flow
- −1,615.0%
- Total debt
- +2,692.8%
Quarter to June 2026, against a year earlier
9.51
0.21
+2.26%
Follow PTHS
Alert me
Pelthos Therapeutics Inc. (PTHS) P/E ratio
Pelthos Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VERU Veru Inc. compare | n/m |
| ELTX Elicio Therapeutics, Inc. compare | n/m |
| PTHS Pelthos Therapeutics Inc. | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| GRCE Grace Therapeutics, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| IBO Impact Biomedical Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)